These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12558462)

  • 1. Losartan in diabetic nephropathy.
    Carswell CI; Goa KL
    Drugs; 2003; 63(4):407-14; discussion 415-6. PubMed ID: 12558462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
    Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
    Shahinfar S; Dickson TZ; Ahmed T; Zhang Z; Ramjit D; Smith RD; Brenner BM;
    Kidney Int Suppl; 2002 Dec; (82):S64-7. PubMed ID: 12410858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF; Lyle PA;
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
    N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B; Gleim G; Panish J
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
    Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
    Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
    Doggrell SA
    Expert Opin Pharmacother; 2002 May; 3(5):625-8. PubMed ID: 11996640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
    Chan JC; Wat NM; So WY; Lam KS; Chua CT; Wong KS; Morad Z; Dickson TZ; Hille D; Zhang Z; Cooper ME; Shahinfar S; Brenner BM; Kurokawa K;
    Diabetes Care; 2004 Apr; 27(4):874-9. PubMed ID: 15047641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
    Boner G; Cooper ME; McCarroll K; Brenner BM; de Zeeuw D; Kowey PR; Shahinfar S; Dickson T; Crow RS; Parving HH;
    Diabetologia; 2005 Oct; 48(10):1980-7. PubMed ID: 16082528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losartan and end-organ protection--lessons from the RENAAL study.
    Kowey PR; Dickson TZ; Zhang Z; Shahinfar S; Brenner BM;
    Clin Cardiol; 2005 Mar; 28(3):136-42. PubMed ID: 15813620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
    Souchet T; Durand Zaleski I; Hannedouche T; Rodier M; Gaugris S; Passa P;
    Diabetes Metab; 2003 Feb; 29(1):29-35. PubMed ID: 12629445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
    Mohanram A; Zhang Z; Shahinfar S; Lyle PA; Toto RD
    Kidney Int; 2008 Mar; 73(5):630-6. PubMed ID: 18094675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.